These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 38321747)

  • 1. Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry.
    Guo WH; Qi X; Yu X; Liu Y; Chung CI; Bai F; Lin X; Lu D; Wang L; Chen J; Su LH; Nomie KJ; Li F; Wang MC; Shu X; Onuchic JN; Woyach JA; Wang ML; Wang J
    Nat Commun; 2020 Aug; 11(1):4268. PubMed ID: 32848159
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient Targeted Degradation via Reversible and Irreversible Covalent PROTACs.
    Gabizon R; Shraga A; Gehrtz P; Livnah E; Shorer Y; Gurwicz N; Avram L; Unger T; Aharoni H; Albeck S; Brandis A; Shulman Z; Katz BZ; Herishanu Y; London N
    J Am Chem Soc; 2020 Jul; 142(27):11734-11742. PubMed ID: 32369353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Orally Bioavailable, and Blood-Brain Barrier Penetrant PROTAC Degrader of Leucine-Rich Repeat Kinase 2.
    Liu X; Kalogeropulou AF; Domingos S; Makukhin N; Nirujogi RS; Singh F; Shpiro N; Saalfrank A; Sammler E; Ganley IG; Moreira R; Alessi DR; Ciulli A
    J Am Chem Soc; 2022 Sep; 144(37):16930-16952. PubMed ID: 36007011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of the First Potent DYRK2 Proteolysis Targeting Chimera Degraders.
    Chen J; Zhu W; Zhang W; Tong Y; Xu F; Pang J
    ACS Med Chem Lett; 2024 May; 15(5):659-666. PubMed ID: 38746900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and evaluation of BTK-targeting PROTACs with optimized bioavailability
    Sun Y; Yang Z; Zhang Z; Li Z; Guo L; Pan H; Luo X; Liu D; Rao Y
    RSC Med Chem; 2023 Aug; 14(8):1562-1566. PubMed ID: 37593574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Merging PROTAC and molecular glue for degrading BTK and GSPT1 proteins concurrently.
    Yang Z; Sun Y; Ni Z; Yang C; Tong Y; Liu Y; Li H; Rao Y
    Cell Res; 2021 Dec; 31(12):1315-1318. PubMed ID: 34417569
    [No Abstract]   [Full Text] [Related]  

  • 7. BTK degraders tackle drug resistance.
    Villanueva MT
    Nat Rev Drug Discov; 2024 Mar; 23(3):173. PubMed ID: 38336888
    [No Abstract]   [Full Text] [Related]  

  • 8. PROTAC for Bruton's tyrosine kinase degradation alleviates inflammation in autoimmune diseases.
    Zhu C; Yang Z; Zhang Y; Li Z; Li G; Yang B; Kang N; Wang J; Sun Y; Ding N; Rao Y; Liu W
    Cell Discov; 2024 Aug; 10(1):82. PubMed ID: 39107285
    [No Abstract]   [Full Text] [Related]  

  • 9. Correction: Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer.
    Gut; 2024 Jul; 73(8):e10. PubMed ID: 38866472
    [No Abstract]   [Full Text] [Related]  

  • 10. Discovery of Ibrutinib-based BTK PROTACs with in vivo anti-inflammatory efficacy by inhibiting NF-κB activation.
    Huang J; Ma Z; Yang Z; He Z; Bao J; Peng X; Liu Y; Chen T; Cai S; Chen J; Zeng Z
    Eur J Med Chem; 2023 Nov; 259():115664. PubMed ID: 37487306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel BTK PROTACs with improved metabolic stability via linker rigidification strategy.
    Chen S; Chen Z; Lu L; Zhao Y; Zhou R; Xie Q; Shu Y; Lin J; Yu X; Wang Y
    Eur J Med Chem; 2023 Jul; 255():115403. PubMed ID: 37119666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next-generation Bruton's Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives.
    Das D; Wang J; Hong J
    Curr Top Med Chem; 2022; 22(20):1674-1691. PubMed ID: 35927919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress in the development of small molecular inhibitors of the Bruton's tyrosine kinase (BTK) as a promising cancer therapy.
    Liu XJ; Xu-Liu ; Pang XJ; -Ying Yuan X; Yu GX; Li YR; Guan YF; Zhang YB; Song J; Zhang QR; Zhang SY
    Bioorg Med Chem; 2021 Oct; 47():116358. PubMed ID: 34479103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Novel Potent and Fast BTK PROTACs for the Treatment of Osteoclasts-Related Inflammatory Diseases.
    Huang J; Ma Z; Peng X; Yang Z; Wu Y; Zhong G; Ouyang T; Chen Z; Liu Y; Wang Q; Chen J; Chen T; Zeng Z
    J Med Chem; 2024 Feb; 67(4):2438-2465. PubMed ID: 38321747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Novel Bruton's Tyrosine Kinase PROTACs with Enhanced Selectivity and Cellular Efficacy.
    Li YQ; Lannigan WG; Davoodi S; Daryaee F; Corrionero A; Alfonso P; Rodriguez-Santamaria JA; Wang N; Haley JD; Tonge PJ
    J Med Chem; 2023 Jun; 66(11):7454-7474. PubMed ID: 37195170
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.